Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort
Kristine M. Erlandson, Linda N. Geng, Caitlin Selvaggi, Tanayott Thaweethai, Peter Chen, Nathan Erdmann, Jason D. Goldman, Timothy J. Henrich, Mady Hornig, Elizabeth W. Karlson, Stuart D. Katz, Chun Kim, Sushma K. Cribbs, Adeyinka O. Laiyemo, Rebecca Letts, Janet Lin, Jai Marathe, Sairam Parthasarathy, Thomas F. Patterson, Brittany D. Taylor, Elizabeth R. Duffy, Monika Haack, Boris Jülg, Gabrielle Maranga, Carla Hernandez, Nora G. Singer, Jenny E. Han, Priscilla Pemu, Hassan Brim, Hassan Ashktorab, Alexander W. Charney, Juan P. Wisnivesky, Jenny J. Lin, Helen Y. Chu, Minjoung Go, Upinder Singh, Emily B. Levitan, Paul Goepfert, Janko Ž. Nikolich, Harvey Hsu, Michael J. Peluso, J. Daniel Kelly, Megumi J. Okumura, Valerie J. Flaherman, John G. Quigley, Jerry A. Krishnan, Mary Beth Scholand, Rachel Hess, Torri D. Metz, Maged M. Costantine, Dwight J. Rouse, Barbara S. Taylor, Mark P. Goldberg, Gailen D. Marshall, Jeremy P. Wood, David E. Warren, Leora Horwitz, Andrea S. Foulkes, Grace A. McComsey, RECOVER-Adult Cohort, Jeffrey Burns, Serena Spudich, L. Charles Bailey, Mine Cicek, Melissa Cortez, Felicia Davis Blakley, Andrea S. Foulkes, David C. Goff, Stuart D. Katz, Jessica Lasky‐Su, Torri Metz, Lisa T. Newman, Igho Ofotokun, Sudha Seshadri, Melissa Stockwell, James R. Stone, Brittany D. Taylor, PJ Utz, Neely Williams, Hassan Ashktorab, Jeannette M. Beasley, Karyn Bishof, Yu Chen, Lori B. Chibnik, Dani Dumitriu, Jennifer Frontera, Paul Goepfert, Sylvie Goldman, Stephen M. Hewitt, Matthew J. Huentelman, Barbara I. Karp, Jerry A. Krishnan, Sarah Laury, Bruce D. Levy, Janko Nikolich-Zugich, Margaret J. Ochocinska, Laura Pace, Alice Perlowski, William Reeves, Juan C. Salazar
Abstract
BACKGROUND: There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC). OBJECTIVE: To investigate clinical laboratory markers of SARS-CoV-2 and PASC. DESIGN: Propensity score-weighted linear regression models were fitted to evaluate differences in mean laboratory measures by prior infection and PASC index (≥12 vs. 0). (ClinicalTrials.gov: NCT05172024). SETTING: 83 enrolling sites. PARTICIPANTS: RECOVER-Adult cohort participants with or without SARS-CoV-2 infection with a study visit and laboratory measures 6 months after the index date (or at enrollment if >6 months after the index date). Participants were excluded if the 6-month visit occurred within 30 days of reinfection. MEASUREMENTS: Participants completed questionnaires and standard clinical laboratory tests. RESULTS: levels was attenuated after participants with preexisting diabetes were excluded. Among participants with prior infection, no meaningful differences in mean laboratory values were found between those with a PASC index of 12 or higher and those with a PASC index of zero. LIMITATION: Whether differences in laboratory markers represent consequences of or risk factors for SARS-CoV-2 infection could not be determined. CONCLUSION: Overall, no evidence was found that any of the 25 routine clinical laboratory values assessed in this study could serve as a clinically useful biomarker of PASC. PRIMARY FUNDING SOURCE: National Institutes of Health.